This product is a GM-CSF expressing oncolytic herpes simplex virus, which is based on HSV-2 with ICP10PK deleted. The herpes simplex virus type 2 (HSV-2) protein ICP10PK has anti-apoptotic activity independent of other viral proteins that ICP10 PK-induced activation of the ERK survival pathway results in Bag-1 upregulation. The deletion of ICP10PK can enhance the oncolytic activity. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.
Specifications
Family
Herpesviridae
Species
Herpes simplex virus
Serotype
Herpes simplex virus 2
Backbone
HSV-2 (ΔICP10PK)
Backbone Background
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony-stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, natural killer cells, endothelial cells and fibroblasts that functions as a cytokine. Unlike granulocyte colony-stimulating factor, which specifically promotes neutrophil proliferation and maturation, GM-CSF affects more cell types, especially macrophages and eosinophils.
Customer Reviews and Q&As
There are currently no customer reviews or questions for GM-CSF-expressing Oncolytic Herpes Simplex Virus 2 (ΔICP10PK), IE4/5-GM-CSF (CyOV-0339XY). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.